GSK

As our momentum this year continues, our CEO Emma Walmsley shared her reflections on our Q2 2024 results. Read more ⤵

News for #Investors and #Media Explore our Q2 2024 figures at a glance. https://www.gsk.com/en-gb/. $GSK

News for #Investors and #Media Watch our CEO Emma Walmsley as she shares our Q2 results, with continued strong performance and upgraded full-year guidance for 2024. For more, visit https://www.gsk.com/en-gb/ $GSK #Q2Results

#Investors and #Media Please read our cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures for our Q2 2024 results. CER% represents constant exchange rates. £% or AER% represents actual exchange rates. $GSK For investors: https://gsk.to/3LJ8b0W

“Science is giving us all these solutions to prevent disease before it even starts, but if we don't have the right policies in place to unlock funding, make access easy for people and build the belief, the right education, what does it matter?” Read The New York Times' interview with Kate Hashey, MA, MPH about how prioritizing #prevention and ensuring access to #vaccines for everyone is part of GSK’s vision to improve #publichealth around the globe 🌎➡️ https://gsk.to/3yog60x

#News for #investors and #media: Today we announced that we have entered into an agreement with Flagship Pioneering to discover future medicines and vaccines for patients. Find out more: https://gsk.to/3WkUgDj

Chronic hepatitis B is a long-lasting and potentially life-threatening liver infection caused by the hepatitis B virus. Even with the progress that has been made thanks to vaccination, CHB affects 257 million people around the world. We are inspired by Sophia - and people like her - to continue innovating in this space. That is why we are proud to partner with The World Hepatitis Alliance on this #WorldHepatitisDay to raise awareness of how much more needs to be done for those living with CHB. It is time for action to meet the needs of the people living with CHB.

“There are three things necessary to ending the HIV/AIDS epidemic,” says Dr Nneka Nwokolo, Head of Global Patient Engagement for ViiV Healthcare, our specialist HIV company. “One is to test everybody so that you identify people living with HIV. Second is to treat people who you find have HIV. And third is to prevent HIV from occurring in people who don’t have it. You cannot end HIV without all of them, and prevention is key.” 🔗 Find out what it means to change the course of disease through prevention: https://gsk.me/3SqOMWa #AIDS2024

At #AIDS2024, we are showcasing our latest innovation to develop the next generation of treatment and prevention options for people living with #HIV. By working together, we can limit the impact of HIV. Meet Tammeka, a change maker, innovator and equality advocate. Tammeka and her team are developing cutting-edge digital solutions to enable more inclusive clinical trials. Their groundbreaking research also includes transgender women in all-women studies, promoting inclusivity and creating a level playing field. Learn more about our goal to end HIV and explore career opportunities at https://gsk.to/4c3cfno #GSKCareers #WeAreGSK.

HIV remains one of the world’s biggest health epidemics, with 1.3 million new diagnoses annually, and more than 39 million people living with HIV. There is not yet a cure for HIV; however, 40 years of innovation has transformed HIV into a manageable, chronic health condition, enabling people living with HIV to lead long and healthy lives. Despite this progress, HIV stigma is still pervasive and impacts people living with HIV and their care. Our goal is to minimise the impact of HIV on people’s lives by treating and preventing the disease, and tackling HIV-related stigma. Find out more: https://gsk.to/3WFe2Le 👈 #AIDS2024